1. Home
  2. QH vs IMRN Comparison

QH vs IMRN Comparison

Compare QH & IMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

QH

Quhuo Limited American Depository Shares

N/A

Current Price

$2.79

Market Cap

8.0M

ML Signal

N/A

Logo Immuron Limited

IMRN

Immuron Limited

N/A

Current Price

$0.82

Market Cap

7.7M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
QH
IMRN
Founded
2012
1994
Country
China
Australia
Employees
N/A
N/A
Industry
Business Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
8.0M
7.7M
IPO Year
2019
2016

Fundamental Metrics

Financial Performance
Metric
QH
IMRN
Price
$2.79
$0.82
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
2.5K
★ 16.7K
Earning Date
11-17-2026
08-28-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$16.39
Revenue Next Year
N/A
N/A
P/E Ratio
$2.86
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.07
$0.68
52 Week High
$12.81
$1.99

Technical Indicators

Market Signals
Indicator
QH
IMRN
Relative Strength Index (RSI) 31.03 33.29
Support Level $0.08 $0.73
Resistance Level $5.32 $0.89
Average True Range (ATR) 0.14 0.07
MACD -0.02 -0.00
Stochastic Oscillator 5.75 27.32

Price Performance

Historical Comparison
QH
IMRN

About QH Quhuo Limited American Depository Shares

Quhuo Ltd is a gig economy platform focusing on local life services in China. It provide tech-enabled, end-to-end operational solutions to consumer service businesses, including on-demand delivery solutions, mobility service solutions, housekeeping and accommodation solutions, and other services. Its three operating segments, include (i) on-demand delivery solutions, (ii) mobility service solutions, and (iii) housekeeping and accommodation solutions and other services. It generates maximum of its revenue from the on-demand delivery solutions segment.

About IMRN Immuron Limited

Immuron Ltd is a commercial- and clinical-stage biopharmaceutical company focused on the development and commercialization of specifically targeted polyclonal antibodies. Its oral polyclonal antibodies offer delivery within the GI tract and can target viruses or bacteria and neutralize toxins at mucosal surfaces. The Company markets Travelan in Australia, an over-the-counter orally administered passive immunotherapeutic product indicated to reduce the risk of traveler's diarrhea and minor gastrointestinal disorders. Its products include Travelan, ProIBS and Protectyn. Its segments are Research and Development and Hyper-immune products, with Hyper-immune products generating maximum revenue. Australia generates maximum revenue.

Share on Social Networks: